Locally stimulating intratumoral NK cells or developing XCR1 ligands to attract cDC1 into the TME could be an attractive therapeutic means of eliciting anti-tumor immunity and increasing the response rate to immunotherapy. This evidence concerns the gene XCR1 and neoplasm.